scholarly article | Q13442814 |
P356 | DOI | 10.1002/AJMG.A.37811 |
P698 | PubMed publication ID | 27327493 |
P2093 | author name string | Debomoy K Lahiri | |
Tori L Schaefer | |||
Balmiki Ray | |||
Craig A Erickson | |||
Logan K Wink | |||
Ernest V Pedapati | |||
Bayon Baindu | |||
P2860 | cites work | The neurobehavioral and molecular phenotype of Angelman Syndrome. | Q52662222 |
Characterization of Human hect Domain Family Members and Their Interaction with UbcH5 and UbcH7 | Q58376444 | ||
Partial duplication of the APBA2 gene in chromosome 15q13 corresponds to duplicon structures | Q21266627 | ||
Angelman syndrome: a review of the clinical and genetic aspects | Q24678174 | ||
From UBE3A to Angelman syndrome: a substrate perspective | Q26781685 | ||
Structure of an E6AP-UbcH7 complex: insights into ubiquitination by the E2-E3 enzyme cascade | Q27620360 | ||
Increased secreted amyloid precursor protein-α (sAPPα) in severe autism: proposal of a specific, anabolic pathway and putative biomarker | Q28478681 | ||
Reversal of fragile X phenotypes by manipulation of AβPP/Aβ levels in Fmr1KO mice | Q30473360 | ||
Abnormal intracellular accumulation and extracellular Aβ deposition in idiopathic and Dup15q11.2-q13 autism spectrum disorders | Q34261556 | ||
The E6-Ap ubiquitin-protein ligase (UBE3A) gene is localized within a narrowed Angelman syndrome critical region | Q34428426 | ||
Impact of acamprosate on plasma amyloid-β precursor protein in youth: a pilot analysis in fragile X syndrome-associated and idiopathic autism spectrum disorder suggests a pharmacodynamic protein marker | Q34620558 | ||
Fragile X Syndrome and Alzheimer's Disease: Another story about APP and beta-amyloid | Q34632916 | ||
Autism, Alzheimer disease, and fragile X: APP, FMRP, and mGluR5 are molecular links | Q34953710 | ||
The ubiquitin-proteasome pathway: the complexity and myriad functions of proteins death | Q36184000 | ||
Genomic and functional profiling of duplicated chromosome 15 cell lines reveal regulatory alterations in UBE3A-associated ubiquitin-proteasome pathway processes | Q40323242 | ||
Clinical research on Angelman syndrome in the United Kingdom: Observations on 82 affected individuals | Q48317479 | ||
Clinical, cytogenetic, and molecular diagnosis of Angelman syndrome: estimated prevalence rate in a Danish county. | Q50556444 | ||
Angelman syndrome: are the estimates too low? | Q52181420 | ||
P433 | issue | 9 | |
P407 | language of work or name | English | Q1860 |
P304 | page(s) | 2334-2337 | |
P577 | publication date | 2016-06-21 | |
P1433 | published in | American Journal of Medical Genetics | Q4744254 |
P1476 | title | Analysis of peripheral amyloid precursor protein in Angelman Syndrome. | |
P478 | volume | 170 |
Q39012491 | Angelman syndrome: Current and emerging therapies in 2016. |
Q64060256 | Dysfunction of the ubiquitin ligase E3A Ube3A/E6-AP contributes to synaptic pathology in Alzheimer's disease |
Q47764625 | Eye gaze and pupillary response in Angelman syndrome |
Q38826557 | Novel roles of amyloid-beta precursor protein metabolites in fragile X syndrome and autism. |
Q90263774 | Peripheral Amyloid Precursor Protein Derivative Expression in Fragile X Syndrome |
Q30235312 | Role of Genetics in the Etiology of Autistic Spectrum Disorder: Towards a Hierarchical Diagnostic Strategy |
Search more.